Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

about

Cost of Treatment for Relapsed/Refractory Multiple Myeloma Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

P2860

Q36480589-46D08254-B44C-4E6D-9AE2-4BCA099423C3 Q38981247-41AB44A2-B6B4-46CE-A6A9-3EBEC538FBD7

P2860

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Item

http://www.wikidata.org/entity/Q35809982

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@ast

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@en

type

Item

label

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@ast

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@en

prefLabel

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@ast

Estimating the Costs of Therap ...... le Myeloma: A Model Framework.

@en

P1476

Estimating the Costs of Therap ...... ple Myeloma: A Model Framework

@en

P2093

Anuja Roy

http://www.w3.org/2001/XMLSchema#string

David S Siegel

http://www.w3.org/2001/XMLSchema#string

Denise Globe

http://www.w3.org/2001/XMLSchema#string

Emil T Kuriakose

http://www.w3.org/2001/XMLSchema#string

Jonathan K Kish

http://www.w3.org/2001/XMLSchema#string

Kristen Migliaccio-Walle

http://www.w3.org/2001/XMLSchema#string

Lisa Bloudek

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Total cost comparison in relapsed/refractory multiple myeloma.

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Multiple myeloma: charging toward a bright future.

P304

204-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26157542

http://www.w3.org/2001/XMLSchema#string

P932

4489189

http://www.w3.org/2001/XMLSchema#string

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

about

P2860

P2860

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932